Novel quinazolin-4-one derivatives as potentiating agents of doxorubicin cytotoxicity

Add time:07/23/2019    Source:sciencedirect.com

We report the design, synthesis and biological evaluation of 17 novel 8-aryl-2-morpholino-3,4-dihydroquinazoline derivatives based on the standard model of DNA-PK and PI3K inhibitors. Novel compounds are sub-divided into two series where the second series of five derivatives was designed to have a better solubility profile over the first one. A combination of in vitro and in silico techniques suggested a plausible synergistic effect with doxorubicin of the most potent compound 14d on cell proliferation via DNA-PK and poly(ADP-ribose) polymerase-1 (PARP-1) inhibition, while alone having a negligible effect on cell proliferation.

We also recommend Trading Suppliers and Manufacturers of N-(2-hydroxyethyl)doxorubicin (cas 103851-20-3). Pls Click Website Link as below: cas 103851-20-3 suppliers

Prev:Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine
Next:Determination of Nonspherical Morphology of Doxorubicin-Loaded Liposomes by Atomic Force Microscopy)